CClinicalTrials.gg
CompletedNCT06350435Updated Jul 16, 2024

Effects of Prefabricated Foot Orthoses With and Without Metatarsal Pads on Central Metatarsalgia

An interventional study of Prefabricated foot orthoses (PFO) with metatarsal pads and Prefabricated foot orthoses (PFO) without metatarsal pads in Metatarsalgia, sponsored by Chinese University of Hong Kong. Completed at 1 site in Hong Kong. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Compare the effects of prefabricated foot orthoses with and without metatarsal pads on pain intensity in the 2nd to 4th metatarsophalangeal joints, foot and ankle functional abilities as well as the occurrence of plantar callosities among patients with central metatarsalgia.

Read the detailed description

Metatarsalgia is a common condition that affecting about 10% of the general population. Central metatarsalgia involves pathology of the 2nd to 4th metatarsal and their respective metatarsophalangeal joints. This randomized control trial is designed to compare the effects of prefabricated foot orthoses with and without metatarsal pads on pain intensity, foot and ankle functional abilities as well as the occurrence of plantar callosities.

02

Conditions studied

  • Metatarsalgia
03

In context

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age ≥ 18 years;
  • Complain of foot pain on the 2nd to 4th MTPJs during walking in shoes, rating the pain intensity as ≥ 50mm on the Visual Analogue Scale (VAS);
  • Able to be ambulant

Exclusion criteria

Exclusion Criteria:

  • Peripheral vascular disease (PVD)
  • Neurological dysfunctions or neuromuscular disorders
  • Active infection, i.e., cellulitis, osteomyelitis, shingles
  • Cognitive impairment
  • History of lower limb surgery and currently undergoing rehabilitation
  • Active ulceration on foot and ankle
  • Current utilization of prescribed insoles
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Experimental Group

    Device: Prefabricated foot orthoses (PFO) with metatarsal pads

  • Other
    Control group

    Device: Prefabricated foot orthoses (PFO) without metatarsal pads

Interventions

  • DevicePrefabricated foot orthoses (PFO) with metatarsal pads

    A pair of prefabricated foot orthoses, each with a metatarsal pad to be affixed underneath

    Also known as: Slimflex® Amber Insoles, Podotech® High Density Metatarsal Pad- Wide Raise SD2121, SD2122, SD2123

  • DevicePrefabricated foot orthoses (PFO) without metatarsal pads

    A pair of prefabricated foot orthoses only

    Also known as: Slimflex® Amber Insoles

06

What researchers measure

Primary outcomes

  1. Pain intensity at the 2nd to 4th metatarsophalangeal joints during walking in shoes on Visual Analogue Scale

    VAS consists of a 100mm-long uninterrupted horizontal line, with 2 verbal description at each end. A score of 0mm represents "no pain" while 100 mm represents "the worst imaginable pain".

    Time frame: Baseline, a follow-up at 4-8 weeks from baseline

Secondary outcomes

  1. Foot and Ankle Outcome Score (FAOS)

    FAOS consists of 42 questions, which are categorized into 5 subdomains: symptoms, pain, activities of daily living, sports and quality of life. Each question id rated on a 5-point Likert scale, ranging from 0 to 4 and subsequently transformed into a normalized score between 0 and 100. A score of 100 indicates absence of symptoms, while a score of 0 indicates the presence of severe symptoms.

    Time frame: Baseline, a follow-up at 4-8 weeks from baseline

  2. Size of callosities and corns on the plantar area of the 2nd to 4th metatarsophalangeal joints

    Time frame: Baseline, a follow-up at 4-8 weeks from baseline

07

Study locations

1 site
  • Pamela Youde Nethersole Eastern Hospital
    Hong Kong, Hong Kong
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06350435
Lead sponsor
Chinese University of Hong Kong
Collaborators
Pamela Youde Nethersole Eastern Hospital
Responsible party
Chan Fung Ting (Student, Chinese University of Hong Kong) — Principal investigator
First posted
Apr 5, 2024
Start date
Jan 26, 2024
Primary completion
Apr 18, 2024
Completion
Apr 18, 2024
Last update
Jul 16, 2024

Study contacts

Fung Ting Chan
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion